...
首页> 外文期刊>Circulation journal >Plasma Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 as a Novel Prognostic Biomarker in Patients With ST-Segment Elevation Acute Myocardial Infarction
【24h】

Plasma Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 as a Novel Prognostic Biomarker in Patients With ST-Segment Elevation Acute Myocardial Infarction

机译:血浆可溶性凝集素样氧化的低密度脂蛋白受体1作为ST段抬高急性心肌梗死患者的新型预后生物标志物。

获取原文
           

摘要

Background: Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) level is a reliable prognostic biomarker in acute coronary syndrome. However, it is unclear whether its plasma level at acute phase is related to the long-term prognosis in patients with ST-segment elevation acute myocardial infarction (STEMI). Methods?and?Results: We prospectively examined the relation between plasma sLOX-1 level on admission and prognosis in 153 consecutive STEMI patients admitted within 24 h of onset. Primary percutaneous coronary intervention was performed in 144 patients. The patients were divided into 2 groups by the median value (71 pg/ml) of plasma sLOX-1 level on admission [sLOX-1 level ≤71 pg/ml (n=77) and >71 pg/ml (n=76)], and were followed for median of 1,156 days. All-cause mortality and the combined endpoints of major adverse cardiovascular events (MACE) defined as cardiovascular mortality and recurrent MI were both significantly higher in patients with sLOX-1 values above median than in those below median (25.0% vs. 3.9%, P
机译:背景:可溶性凝集素样氧化型低密度脂蛋白受体1(sLOX-1)水平是急性冠脉综合征的可靠预后生物标志物。然而,尚不清楚ST段抬高急性心肌梗死(STEMI)患者的急性期血浆水平是否与长期预后有关。方法和结果:我们前瞻性检查了发病24 h内连续入院的153例STEMI患者的血浆sLOX-1水平与入院率和预后的关系。 144例患者进行了主要的经皮冠状动脉介入治疗。根据入院时血浆sLOX-1水平的中位数(71 pg / ml)将患者分为两组[sLOX-1水平≤71pg / ml(n = 77)和> 71 pg / ml(n = 76) )],中位数为1,156天。 sLOX-1值高于中位数的患者的全因死亡率和主要不良心血管事件(MACE)的合并终点均被定义为心血管疾病死亡率和复发性MI均显着高于中位数以下的患者(25.0%vs. 3.9%,P

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号